Jointlieve (Devil's Claw Extract)

Devil's Claw contains the iridoid harpagoside, which is believed to inhibit cyclooxygenase enzymes and modulate inflammatory cytokines. By decreasing prostaglandin synthesis, it reduces inflammation in joints and surrounding tissues, providing an analgesic effect that contributes to pain relief.

The appropriate dose of Jointlieve is determined by the prescribing health professional based on the individual’s condition, age, and other factors. Patients should follow the dosage instructions provided on the product label or by their clinician and should not exceed the recommended amount.

Safety data for Devil’s Claw extract in pregnancy and lactation are limited, and the product is not specifically approved for these populations. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Jointlieve.

To place an order, submit an enquiry on the Jointlieve product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with standard NSAIDs, Jointlieve offers a herbal alternative that may have a lower risk of gastrointestinal ulceration but provides modest anti‑inflammatory effects. Unlike glucosamine, Devil’s Claw primarily targets inflammatory pathways rather than cartilage repair, making it suitable for patients seeking natural pain relief with a different mechanism.

Jointlieve should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral herbal supplement.

Jointlieve is taken orally, typically with a glass of water. The product may be available as capsules or tablets; patients should swallow the dosage form whole and avoid crushing unless directed by a healthcare professional. Administration should follow the label instructions or the prescribing clinician’s guidance.

Although generally well tolerated, serious adverse reactions can include severe allergic responses such as rash, swelling, or anaphylaxis, and rare cases of liver enzyme elevation. Patients with bleeding disorders or those taking anticoagulant therapy should be monitored closely for increased bleeding risk. Prompt medical attention is advised if serious symptoms develop.

Individuals with known hypersensitivity to Devil’s Claw or related plant species should avoid Jointlieve. Those with active bleeding disorders, uncontrolled hypertension, or who are currently using anticoagulants, antiplatelet drugs, or high‑dose NSAIDs should consult a healthcare professional before use. Pregnant or nursing women should also seek medical advice prior to taking the supplement.